Related Experiment Videos
Electroencephalographic study of an infant with phosphoribosylpyrophosphate synthetase deficiency
The Tohoku Journal of Experimental Medicine
|May 1, 1975
Insights
A rare enzyme defect caused hypouricemia and intellectual disability in an infant. Hypsarrhythmia, a type of seizure, improved with ACTH therapy, alongside increased erythrocyte 5-phosphoribosylpyrophosphate synthetase activity.
Area of Science:
- Biochemistry
- Pediatric Neurology
- Genetics
Background:
- A defect in 5-phosphoribosylpyrophosphate synthetase leads to hypouricemia and intellectual disability.
- This enzyme is crucial for purine and pyrimidine synthesis.
- Infantile spasms, or hypsarrhythmia, can be associated with various metabolic disorders.
Purpose of the Study:
- To document the electroencephalogram (EEG) findings in an infant with a 5-phosphoribosylpyrophosphate synthetase defect.
- To evaluate the effect of adrenocorticotropic hormone (ACTH) therapy on seizure activity and enzyme levels.
- To explore the relationship between enzyme activity and neurological improvement.
Main Methods:
- Longitudinal electroencephalogram (EEG) recordings were performed at 4, 7, 10, and 11 months of age.
- The infant received ACTH therapy for observed seizure activity.
- Erythrocyte enzyme activity of 5-phosphoribosylpyrophosphate synthetase was measured.
Main Results:
- Hypsarrhythmia was identified on EEG at 10 months of age.
- ACTH therapy led to a marked improvement in hypsarrhythmia.
- Concomitant with clinical improvement, there was an increase in erythrocyte 5-phosphoribosylpyrophosphate synthetase activity.
Conclusions:
- ACTH therapy may be beneficial in managing seizures associated with 5-phosphoribosylpyrophosphate synthetase deficiency.
- The study suggests a potential link between enzyme activity and neurological status in this condition.
- Further research is warranted to understand the underlying mechanisms and optimize treatment strategies.
Abstract:
In a hypouricemic and mentally retarded infant due to a defect of 5-phosphoribosylpyrophosphate synthetase, electroencephalograms were recorded at the age of 4, 7, 10 and 11 months. Hypsarrhythmia was first observed at the age of 10 months, and markedly improved after ACTH therapy with concomitant increase in the enzyme activity of erythrocytes.